^
    Back
    Association details:
    Biomarker:EGFR E746_A750del
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Tyrosine kinase inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Clinical outcomes of patients with advanced NSCLC with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors.

    Published date:
    05/25/2023
    Excerpt:
    We retrospectively analyzed stage IIIB-IV NSCLC patients with EGFR Ex19del and first-line TKIs therapy. E746_A750del was defined as classic group, and the others as non-classic group….In patients without PM, the mPFS of first-line TKIs in classic group was significantly shorter than non-classic group (13.8 m and 29.7 m, p = 0.026)....In advanced NSCLC patients with EGFR Ex19del, the efficacy of first-line TKIs therapy was affected by the presence of pleural metastasis, Ex19del subtypes and different generation of TKIs.
    DOI:
    10.1200/JCO.2023.41.16_suppl.e21034